ES2968041T3 - Quinolina que modula SERCA y su uso para tratar enfermedades - Google Patents

Quinolina que modula SERCA y su uso para tratar enfermedades Download PDF

Info

Publication number
ES2968041T3
ES2968041T3 ES21845832T ES21845832T ES2968041T3 ES 2968041 T3 ES2968041 T3 ES 2968041T3 ES 21845832 T ES21845832 T ES 21845832T ES 21845832 T ES21845832 T ES 21845832T ES 2968041 T3 ES2968041 T3 ES 2968041T3
Authority
ES
Spain
Prior art keywords
mmol
mixture
compound
water
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21845832T
Other languages
English (en)
Spanish (es)
Inventor
Russell Dahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurodon Corp
Original Assignee
Neurodon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/932,832 external-priority patent/US20200347038A1/en
Application filed by Neurodon Corp filed Critical Neurodon Corp
Application granted granted Critical
Publication of ES2968041T3 publication Critical patent/ES2968041T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES21845832T 2020-07-20 2021-07-19 Quinolina que modula SERCA y su uso para tratar enfermedades Active ES2968041T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/932,832 US20200347038A1 (en) 2014-08-29 2020-07-20 Quinolines that modulate serca and their use for treating disease
PCT/US2021/042235 WO2022020261A1 (en) 2020-07-20 2021-07-19 Quinolines that modulate serca and their use for treating disease

Publications (1)

Publication Number Publication Date
ES2968041T3 true ES2968041T3 (es) 2024-05-06

Family

ID=79729478

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21845832T Active ES2968041T3 (es) 2020-07-20 2021-07-19 Quinolina que modula SERCA y su uso para tratar enfermedades

Country Status (11)

Country Link
EP (1) EP4037685B9 (enExample)
JP (1) JP7705445B2 (enExample)
CN (1) CN116744928A (enExample)
CA (1) CA3186668A1 (enExample)
DK (1) DK4037685T3 (enExample)
ES (1) ES2968041T3 (enExample)
FI (1) FI4037685T3 (enExample)
HU (1) HUE064550T2 (enExample)
PL (1) PL4037685T3 (enExample)
PT (1) PT4037685T (enExample)
WO (1) WO2022020261A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784533B (zh) * 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
CN104302640A (zh) * 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US10772881B2 (en) * 2017-02-27 2020-09-15 Russell Dahl Quinolines that modulate SERCA and their use for treating disease
US20170281611A1 (en) * 2014-08-29 2017-10-05 Eiger Biopharmaceuticals, Inc. Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
US20200347038A1 (en) * 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
CN106966973A (zh) * 2017-05-18 2017-07-21 湖北工业大学 N‑苯基‑n‑(2‑甲基‑8‑喹啉基)苯甲酰胺的制备方法

Also Published As

Publication number Publication date
WO2022020261A1 (en) 2022-01-27
JP7705445B2 (ja) 2025-07-09
FI4037685T3 (fi) 2023-11-27
EP4037685A4 (en) 2022-11-30
DK4037685T3 (en) 2024-01-02
EP4037685B1 (en) 2023-09-20
WO2022020261A9 (en) 2022-09-09
CA3186668A1 (en) 2022-01-27
CN116744928A (zh) 2023-09-12
PT4037685T (pt) 2023-12-28
HUE064550T2 (hu) 2024-03-28
EP4037685B9 (en) 2024-03-06
PL4037685T3 (pl) 2024-04-02
JP2023534992A (ja) 2023-08-15
EP4037685A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
US12144806B2 (en) Quinolines that modulate SERCA and their use for treating disease
ES2552764T3 (es) Métodos para el tratamiento de varias enfermedades y afecciones, y compuestos útiles para los mismos
ES2683994T3 (es) Estabilizadores de transtiretina y su uso para inhibir amiloidosis por transtiretina e interacciones proteína-proteína
ES2891734T3 (es) Derivados de bencimidazol como inhibidores de tirosina quinasa ERBB para el tratamiento del cáncer
CN101778563B (zh) 调节细胞凋亡的组合物和方法
ES2290538T3 (es) Nuevas imidazopiridinas y su uso.
PT2673266T (pt) Sais de fenotiazina diamínio e sua utilização
MD3788045T2 (ro) Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
US20170281611A1 (en) Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
ES2932187T3 (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades
ES2882782T3 (es) Derivados de benzoxaborol amida L-valinato para el tratamiento de enfermedades parasitarias
US11827626B2 (en) Quinolines that modulate SERCA and their use for treating disease
US10772881B2 (en) Quinolines that modulate SERCA and their use for treating disease
US10383867B2 (en) Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders
US20170231973A1 (en) Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases
ES2893001T3 (es) Nuevos derivados de dihidropiranopirimidinona y su uso
EP4037685B1 (en) Quinoline that modulate serca and its use for treating disease
ES2993173T3 (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
ES2805528T3 (es) Inhibidores de 3,5-diaminopirazol quinasa
EP4334294A1 (en) Compounds for use in the treatment of cancer
HK40099648A (en) Quinolines that modulate serca and their use for treating disease
US10730843B1 (en) Quinoxalines useful as cytoprotective agents
US10730839B2 (en) Quinolines as cytoprotective agents
US20190337899A1 (en) Quinoline sulfonamides useful to treat disease
JP2025505820A (ja) サルササポゲニン構造に基づく誘導体およびその医薬組成物の使用